Ian M. Estepan serves as the Executive Vice President and Chief Financial Officer at Sarepta Therapeutics Inc., a position he has held since joining the company in 2017. In his role, Estepan is responsible for overseeing the financial operations and strategy of Sarepta, a leader in precision genetic medicine dedicated to developing transformative therapies for patients with rare diseases. His leadership has been instrumental in guiding the company through significant growth phases, including the successful launch of multiple groundbreaking therapies and the expansion of Sarepta's research and development pipeline. Before joining Sarepta, Estepan held several key financial leadership positions at major biopharmaceutical companies. He was the Chief Financial Officer at Inotek Pharmaceuticals, where he played a critical role in advancing the company's ophthalmic drug development programs. Prior to Inotek, Estepan served as Senior Vice President of Finance and Chief Accounting Officer at Human Genome Sciences, where he was involved in the commercialization of the company's first product, Benlysta, the first new biologic therapy for lupus in over 50 years. His extensive experience in the biopharma industry, combined with his strategic financial acumen, has been pivotal in driving Sarepta's mission to deliver life-altering treatments to patients. Estepan's career is marked by notable achievements in financial strategy and corporate development. He has successfully managed complex financial transactions, including mergers and acquisitions, public offerings, and strategic partnerships, which have significantly contributed to the growth and success of the companies he has served. At Sarepta, his strategic vision continues to support the company's efforts to innovate and expand its therapeutic offerings, ensuring sustainable growth and value creation for stakeholders.